Advertisement

Response

      We appreciate the comments of Ortega-Guillen et al
      • Ortega-Guillen E.
      • Meneses G.
      • Coila E.
      Remarks about retrospective analysis of ivermectin effectiveness on COVID-19 (ICON study).
      and Buonfrate and Bisoffi
      • Buonfrate D.
      • Bisoffi Z.
      Standard dose ivermectin for COVID-19.
      and their interest in our paper.
      To read this article in full you will need to make a payment
      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ortega-Guillen E.
        • Meneses G.
        • Coila E.
        Remarks about retrospective analysis of ivermectin effectiveness on COVID-19 (ICON study).
        Chest. 2021; 159: 2110-2111
        • Buonfrate D.
        • Bisoffi Z.
        Standard dose ivermectin for COVID-19.
        Chest. 2021; 159: 2111-2112
        • Rajter J.C.
        • Sherman M.S.
        • Fatteh N.
        • Vogel F.
        • Sacks J.
        • Rajter J.J.
        Use of ivermectin is associated with lower mortality in hospitalized patients with COVID-19 (ICON study).
        Chest. 2021; 159: 85-92
        • The RECOVERY Collaborative Group
        Dexamethasone in hospitalized patients with Covid-19—preliminary report.
        N Engl J Med. 2020; ([Published online July 17, 2020])https://doi.org/10.1056/NEJMoa2021436
        • Schmith V.D.
        • Zhou J.J.
        • Lohmer L.R.L.
        The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19.
        Clin Pharmacol Ther. 2020; 108: 762-765
        • Caly L.
        • Wagstaff K.
        The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-1 in vitro.
        Antiviral Res. 2020; 178 (104787)
        • Jans D.
        • Wagstaff K.
        Ivermectin as a broad-spectrum host-directed antiviral: the real deal?.
        Cells. 2020; 9: 2100

      Linked Article